FibroGen (FGEN) Stock Price, News & Analysis

Company Overview

FibroGen, Inc., headquartered in San Francisco, California, is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for serious unmet medical needs. Since its founding in 1993, the company has built a diversified portfolio encompassing small molecules and biologics that address anemia, fibrotic diseases and oncology.

The company’s lead product, roxadustat, is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to treat anemia in chronic kidney disease. Roxadustat has received regulatory approval in China, Japan and several other markets, and is being developed globally through strategic partnerships with Astellas Pharma and AstraZeneca. In addition to roxadustat, FibroGen is advancing pamrevlumab, a monoclonal antibody in late-stage trials for idiopathic pulmonary fibrosis and other fibrotic disorders, as well as early-stage oncology assets aimed at modifying the tumor microenvironment.

FibroGen operates research and development centers across North America, Europe and Asia, leveraging both in-house expertise and external collaborations to drive clinical progress. The company’s global footprint enables efficient regulatory engagement and commercialization in multiple jurisdictions, from China’s rapidly growing pharmaceutical market to established regulatory regions such as the United States and Europe.

Under the leadership of President and Chief Executive Officer Tom Neff, FibroGen emphasizes rigorous science and strategic partnerships to accelerate its pipeline. The management team combines biotech innovation with industry experience, steering the company through clinical milestones and regulatory approvals while seeking to bring transformative medicines to patients worldwide.

Key Stats

• Today's Range: $11.17 to $11.75
• 50-Day Range: $5.25 to $12.18
• 52-Week Range: $4.50 to $21.94
• Volume: 10,536 shs
• Average Volume: 64,338 shs
• Market Capitalization: $46.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Moderate Buy

FibroGen Stock Analysis - MarketRank™

FibroGen scored higher than 79% of companies evaluated by MarketBeat, and ranked 223rd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

FibroGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

FibroGen has a consensus price target of $43.00, representing about 274.6% upside from its current price of $11.48.

Amount of Analyst Coverage

FibroGen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of FibroGen is -30.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of FibroGen is -30.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.89% of the float of FibroGen has been sold short.

Short Interest Ratio / Days to Cover

FibroGen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroGen has recently increased by 3.86%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroGen does not currently pay a dividend.

Dividend Growth

FibroGen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.84

Percentage of Shares Shorted

3.89% of the float of FibroGen has been sold short.

Short Interest Ratio / Days to Cover

FibroGen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroGen has recently increased by 3.86%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,485.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.98% of the stock of FibroGen is held by insiders.

Percentage Held by Institutions

72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FGEN Stock Analysis - Frequently Asked Questions

How have FGEN shares performed this year?

FibroGen's stock was trading at $13.2375 on January 1st, 2025. Since then, FGEN stock has decreased by 13.3% and is now trading at $11.48.

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) posted its quarterly earnings data on Monday, August, 11th. The biopharmaceutical company reported ($3.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.25) by $1.13. The biopharmaceutical company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.88 million.
Read the conference call transcript.

When did FibroGen's stock split?

Shares of FibroGen reverse split before market open on Tuesday, June 17th 2025.The 1-25 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did FibroGen IPO?

FibroGen (FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

Top institutional shareholders of FibroGen include Armistice Capital LLC (8.32%), Primecap Management Co. CA (2.22%), Marshall Wace LLP (1.79%) and Geode Capital Management LLC (1.09%). Insiders that own company stock include James A Schoeneck, Thane Wettig, Christine Chung, Mark Eisner, Deyaa Adib and Benjamin Cravatt.
View institutional ownership trends.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FGEN
• CIK: 921299
• Web: www.fibrogen.com
• Phone: (415) 978-1200
• Fax: 415-978-1902
• Employees: 570
• Year Founded: 1993

Price Target and Rating

• Average Price Target for FibroGen: $43.00
• High Price Target: $43.00
• Low Price Target: $43.00
• Potential Upside/Downside: +274.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.58 million
• Net Margins: -3.86%
• Pretax Margin: -163.36%
• Return on Equity: N/A
• Return on Assets: -27.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.04
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $7.35 million
• Price / Sales: 6.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($50.89) per share
• Price / Book: -0.23

Miscellaneous

• Outstanding Shares: 4,044,000
• Free Float: 3,964,000
• Market Cap: $46.43 million
• Optionable: Optionable
• Beta: 0.76